What is the point? How point-of-care sexually transmitted infection tests can impact infected patients

Point of Care

Volumn 9, Issue 1, 2010, Pages 36-46

  Huppert, Jill ^a   Hesse, Elizabeth ^a   Gaydos, Charlotte A ^b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chlamydia; Gonorrhea; HIV; Point of care; STI; Trichomoniasis

Indexed keywords

EID: 77949454719     PISSN: 1533029X     EISSN: 15330303     Source Type: Journal    
DOI: 10.1097/POC.0b013e3181d2d8cc     Document Type: Review

References (64)

1. Centers for Disease Control and Prevention. Sexually transmitted disease surveillance, 2007, Chlamydia. Atlanta, GA: US Department of Health and Human Services; 2008:27-36.
2. Miller WC, Ford CA, Morris M, et al. Prevalence of chlamydial and gonococcal infections among young adults in the United States. JAMA. 2004;291(18):2229-2236.
3. Weinstock H, Berman S, Cates W Jr. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect Sex Reprod Health. 2004;36(1):6-10.
4. Pate MS, Dixon PB, Hardy K, et al. Evaluation of the BioStar Chlamydia OIA assay with specimens from women attending a sexually transmitted disease clinic. J Clin Microbiol. 1998;36(8):2183-2186.
5. Bandea CI, Koumans EH, Sawyer MK, et al. Evaluation of the rapid BioStar optical immunoassay for detection of Chlamydia trachomatis in adolescent women. J Clin Microbiol. 2009;47(1):215-216.
6. Stratton NJ, Hirsch L, Harris F, et al. Evaluation of the rapid CLEARVIEW Chlamydia test for direct detection of chlamydiae from cervical specimens. J Clin Microbiol. 1991;29(7):1551-1553.
7. Skulnick M, Small GW, Simor AE, et al. Comparison of the Clearview Chlamydia test, Chlamydiazyme, and cell culture for detection of Chlamydia trachomatis in women with a low prevalence of infection. J Clin Microbiol. 1991;29(9):2086-2088.
8. Yin YP, Peeling RW, Chen XS, et al. Clinic-based evaluation of Clearview Chlamydia MF for detection of Chlamydia trachomatis in vaginal and cervical specimens from women at high risk in China. Sex Transm Infect. 2006;82(suppl 5):v33-v37.
9. Steingrimsson O, Pawlak C, Van Der Pol B, et al. Multicenter comparative evaluation of two rapid immunoassay methods for the detection of Chlamydia trachomatis antigen in endocervical specimens. Clin Microbiol Infect. 1997;3(6):663-667.
10. Rani R, Corbitt G, Killough R, et al. Is there any role for rapid tests for Chlamydia trachomatis? Int J STD AIDS. 2002;13(1):22-24.
11. Mahilum-Tapay L, Laitila V, Wawrzyniak JJ, et al. New point of care Chlamydia Rapid TestVbridging the gap between diagnosis and treatment: performance evaluation study. BMJ. 2007;335(7631):1190-1194.
12. One-step Chlamydia dipstick test [product insert]. CLIAwaived I. Available at: http://www.cliawaived.com/web/items/pdf/CHLA1004insert.pdf; 2009.
13. MagnaBioSciences L. MagnaBioSciences: A quantum design company. 2000; http://www.magnabiosciences.com/clinicalDiagnostics.html; 2009.
14. Centers for Disease Control and Prevention. Sexually transmitted disease surveillance, 2007, Gonorrhea. Atlanta, GA: US Department of Health and Human Services; 2008:37-43.
15. Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines, 2006, Clinical Prevention and Guidance. Atlanta, GA: US Department of Health and Human Services; 2006.
16. Benzaken AS, Galban EG, Antunes W, et al. Diagnosis of gonococcal infection in high risk women using a rapid test. Sex Transm Infect. 2006;82(suppl 5):v26-v28.
17. Food and Drug Administration. 510(k) Summary: Chlamydia OIA Assay. 2003; http://www.accessdata.fda.gov/cdrh-docs/pdf2/k023947.pdf. Accessed 2009.
18. Theodore M, Hook E, Mableton S, et al. Use of Thermo BioStar Optical Immunoassay (OIA) as a point-of-care assay for Chlamydia trachomatis and Neisseria gonorrhoeae in sexually transmitted disease clinics. Paper presented at: International Society for STD Research 14th Annual Meeting2001. Berlin.
19. Inverness Medical I. BioStar OIAGC [package insert]. Available at: http://rapiddiagnostictesting.com/PDF%20Files/OIA-GC-Brochure-02476.04.pdf. Accessed August 31, 2009.
20. Alary M, Gbenafa-Agossa C, Aina G, et al. Evaluation of a rapid point-of-care test for the detection of gonococcal infection among female sex workers in Benin. Sex Transm Infect. 2006;82(suppl 5):v29-v32.
21. Cortez Diagnostics. OneStep RapiDip Gonorrhea InstaTest [product insert]. Available at: http://www.rapidtest.com/Gonorrhea-176512.pdf; 2006.
22. Miller WC, Zenilman JM. Epidemiology of chlamydial infection, gonorrhea, and trichomoniasis in the United States-2005. Infect Dis Clin North Am. 2005;19(2):281-296.
23. Madico G, Quinn TC, Rompalo A, et al. Diagnosis of Trichomonas vaginalis infection by PCR using vaginal swab samples. J Clin Microbiol. 1998;36(11):3205-3210.
24. Wendel KA, Erbelding EJ, Gaydos CA, et al. Trichomonas vaginalis polymerase chain reaction compared with standard diagnostic and therapeutic protocols for detection and treatment of vaginal trichomoniasis. Clin Infect Dis. 2002;35(5):576-580.
25. Huppert JS, Mortensen JE, Reed JL, et al. Rapid antigen testing compares favorably with transcription-mediated amplification assay for the detection of Trichomonas vaginalis in young women. Clin Infect Dis. 2007;45(2):194-198.
26. Van Der Pol B, Kwok C, Pierre-Louis B, et al. Trichomonas vaginalis infection and human immunodeficiency virus acquisition in African women. J Infect Dis. 2008;197(4):548-554.
27. Gaydos CA. Rapid tests for sexually transmitted diseases. Curr Infect Dis Rep. 2006;8(2):115-124.
28. Miller GA, Klausner JD, Coates TJ, et al. Assessment of a rapid antigen detection system for Trichomonas vaginalis infection. Clin Diagn Lab Immunol. 2003;10(6):1157-1158.
29. Kurth A, Whittington WL, Golden MR, et al. Performance of a new, rapid assay for detection of Trichomonas vaginalis. J Clin Microbiol. 2004;42(7):2940-2943.
30. Huppert JS, Batteiger BE, Braslins P, et al. Use of an immunochromatographic assay for rapid detection of Trichomonas vaginalis in vaginal specimens. J Clin Microbiol. 2005;43(2):684-687.
31. Pattullo L, Griffeth S, Ding L, et al. Stepwise diagnosis of Trichomonas vaginalis infection in adolescent women. J Clin Microbiol. 2009;47(1):59-63.
32. Campbell L, Woods V, Lloyd T, et al. Evaluation of the OSOM Trichomonas rapid test versus wet preparation examination for detection of Trichomonas vaginalis vaginitis in specimens from women with a low prevalence of infection. J Clin Microbiol. 2008;46(10):3467-3469.
33. Genzyme Diagnostics. OSOM Trichomonas rapid test [product insert]. Genzyme Corporation.
34. Briselden AM, Hillier SL. Evaluation of Affirm VP Microbial Identification Test for Gardnerella vaginalis and Trichomonas vaginalis. J Clin Microbiol. 1994;32(1):148-152.
35. DeMeo LR, Draper DL, McGregor JA, et al. Evaluation of a deoxyribonucleic acid probe for the detection of Trichomonas vaginalis in vaginal secretions. Am J Obstet Gynecol. 1996;174(4):1339-1342.
36. Brown HL, Fuller DD, Jasper LT, et al. Clinical evaluation of Affirm VPIII in the detection and identification of Trichomonas vaginalis, Gardnerella vaginalis, and Candida species in vaginitis/vaginosis. Infect Dis Obstet Gynecol. 2004;12(1):17-21.
37. Lowe NK, Neal JL, Ryan-Wenger NA. Accuracy of the clinical diagnosis of vaginitis compared with a DNA probe laboratory standard. Obstet Gynecol. 2009;113(1):89-95.
38. Becton Dickinson. Affirm VPIII Microbial Identification System; 2003.
39. Hall HI, Song R, Rhodes P, et al. Estimation of HIV incidence in the United States. JAMA. 2008;300(5):520-529.
40. OraSure. OraQuick Advance Rapid HIV-1/2 Antibody Test [product insert]. 2007; Available at: http://www.orasure.com/docs/pdfs/products/oraquick-advance/ OraQuick-Advance-Package-Insert-English.pdf. Accessed August 31, 2009.
41. Delaney KP, Branson BM, Uniyal A, et al. Performance of an oral fluid rapid HIV-1/2 test: experience from four CDC studies. AIDS. 2006;20(12):1655- 1660.
42. Holguín A, Gutierrez M, Portocarrero N, et al. Performance of OraQuick Advance Rapid HIV-1/2 Antibody Test for detection of antibodies in oral fluid and serum/plasma in HIV-1+ subjects carrying different HIV-1 subtypes and recombinant variants. J Clin Virol. 2009;45(2):150-152.
43. Stekler JD, Swenson PD, Coombs RW, et al. HIV testing in a high-incidence population: is antibody testing alone good enough? Clin Infect Dis. 2009;49(3):444-453.
44. Reveal G3 Rapid HIV-1 Antibody Test [product insert]. Available at: http://www.medmira.com/images/Reveal%20PDFs/g3-insert.pdf; 2009.
45. Bio-Rad. Multispot HIV-1/HIV-2 Rapid Test [product insert]. Available at: http://www.bio-rad.com/prd/en/US/adirect/biorad?cmd= BRCatgProductDetail&isFromSearch=true&entryPoint=adirect&catID= 18a8dae4-1f7f-4b49-b25e-9fadf83b3411&vertical=CDG&messageType= BRCatgProductDetail; 2009.
46. Phillips S, Granade TC, Pau CP, et al. Diagnosis of human immunodeficiency virus type 1 infection with different subtypes using rapid tests. Clin Diagn Lab Immunol. 2000;7(4):698-699.
47. Holguín A. Evaluation of three rapid tests for detection of antibodies to HIV-1 non-B subtypes. J Virol Methods. 2004;115(1):105-107.
48. O'Connell RJ, Agan BK, Anderson SA, et al. Sensitivity of the Multispot HIV-1/HIV-2 rapid test using samples from human immunodeficiency virus type 1-positive individuals with various levels of exposure to highly active antiretroviral therapy. J Clin Microbiol. 2006;44(5):1831-1833.
49. Trinity Biotech. Uni-Gold Recombigen HIV [product insert]. 2004; Available at: http://www.fda.gov/downloads/BiologicsBloodVaccines/ BloodBloodProducts/ApprovedProducts/PremarketApprovalsPMAs/ucm093428.pdf. Accessed August 31, 2009.
50. Eller LA, Eller MA, Ouma BJ, et al. Large-scale human immunodeficiency virus rapid test evaluation in a low-prevalence Ugandan blood bank population. J Clin Microbiol. 2007;45(10):3281-3285.
51. Inverness Medical. Clearview HIV 1/2 Stat-Pak [product insert]. Available at: http://www.invernessmedicalpd.com/point-of-care/hiv%e2%81%84stds/ clearview%c2%ae-hiv-stat-pak.aspx. Accessed August 31, 2009.
52. Inverness Medical. Clearview Complete HIV 1/2 [product insert]. Available at: http://www.invernessmedicalpd.com/point-of-care/hiv/stds/clearview- complete-hiv.aspx. Accessed August 31, 2009.
53. World Health Organization. From Bench to Bedside: Setting a path for the translation of improved sexually transmitted infections diagnostics into health care delivery in the developing world Sexually transmitted diseases diagnostics initiative 2001. Available at: www.who.int/std-diagnostics/about-SDI/priorities. htm; 2009.
54. Peeling RW, Holmes KK, Mabey D, et al. Rapid tests for sexually transmitted infections (STIs): the way forward. Sex Transm Infect. 2006;82(suppl 5):v1-v6.
55. Ginsburg K, Slap G. Unique needs of the teen in the health care setting. Curr Opin Pediatr. 1996;8(4):333-337.
56. Gift TL, Pate MS, Hook EW 3rd, et al. The rapid test paradox: when fewer cases detected lead to more cases treated: a decision analysis of tests for Chlamydia trachomatis. Sex Transm Dis. 1999;26(4):232-240.
57. Kahn JA, Bernstein DI, Rosenthal SL, et al. Acceptability of human papillomavirus self testing in female adolescents. Sex Transm Infect. 2005;81(5):408-414.
58. Rogers E. Innovativeness and adopter categories. In: Rogers E, ed. Diffusion of Innovations. 5th ed. New York, NY: The Free Press; 2003:267-300.
59. Huppert JS, Goodman E, Khoury J, et al. Sexually transmitted infection testing and screening in hospital-based primary care visits by women. Obstet Gynecol. 2005;105(2):390-396.
60. Tao G, Tian LH, Peterman TA. Estimating Chlamydia screening rates by using reported sexually transmitted disease tests for sexually active women aged 16 to 25 years in the United States. Sex Transm Dis. 2007;34(3):180-182.
61. National Committee for Quality Assurance. Chlamydia screening. The State of Health Care Quality 2008. National Committee for Quality Assurance; 2008:39-40.
62. Gaydos CA, Dwyer K, Barnes M, et al. Internet-based screening for Chlamydia trachomatis to reach non-clinic populations with mailed self-administered vaginal swabs. Sex Transm Dis. 2006;33(7):451-457.
63. Michel CE, Saison FG, Joshi H, et al. Pitfalls of internet-accessible diagnostic tests: inadequate performance of a CE-marked Chlamydia test for home use. Sex Transm Infect. 2009;85(3):187-189.
64. Shew ML, Hellerstedt WL, Sieving RE, et al. Prevalence of home pregnancy testing among adolescents. Am J Public Health. 2000;90(6):974-976.